Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12239930 | 1.00 | SLC22A2 (0.41) | SLC22A2CYP3A4TMEM97ABCG2GRM2 | |
| SCHEMBL21780072 | 0.90 | GRM2 (0.36) | SLC22A2GRM2THRATHRBMEN1 | |
| SCHEMBL2161654 | 0.90 | GRM2 (0.36) | SLC22A2GRM2THRATHRBMEN1 | |
| SCHEMBL16437768 | 0.89 | SLC22A2 (0.43) | SLC22A2CYP3A4TMEM97ABCG2GRM2 | |
| SCHEMBL18233760 | 0.89 | SLC22A2 (0.43) | SLC22A2CYP3A4TMEM97ABCG2GRM2 | |
| SCHEMBL16437771 | 0.89 | SLC22A2 (0.41) | SLC22A2CYP3A4TMEM97ABCG2GRM2 | |
| SCHEMBL19220590 | 0.87 | SLC22A2 (0.41) | SLC22A2CYP3A4TMEM97ABCG2GRM2 | |
| SCHEMBL19921592 | 0.87 | SLC22A2 (0.48) | SLC22A2CYP3A4TMEM97ABCG2GRM2 | |
| SCHEMBL19157756 | 0.87 | SLC22A2 (0.41) | SLC22A2CYP3A4TMEM97ABCG2GRM2 | |
| SCHEMBL14866503 | 0.87 | SLC22A2 (0.48) | SLC22A2CYP3A4TMEM97ABCG2GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011613-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2018-07-03 | — | — | US | disclosed |
| US-20170368040-A1 | Processes for Preparing Dolutegravir and Cabotegravir and Analogues Thereof | LEK PHARMACEUTICALS D.D. (SI) | 2017-12-28 | — | — | US | disclosed |
| US-20170226128-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| US-9573965-B2 | Process for the preparation of Dolutegravir | AUROBINDO PHARMA LTD (IN) | 2017-02-21 | — | — | US | disclosed |
| US-20160108058-A1 | An improved process for the preparation of Dolutegravir | AUROBINDO PHARMA LTD. (IN) | 2016-04-21 | — | — | US | disclosed |
| US-9200009-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140256937-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| EP-2320908-B9 | Dolutegravir Prodrugs | VIIV HEALTHCARE CO (US) | 2014-06-18 | — | — | EP | disclosed |
| EP-2320908-B1 | Dolutegravir Prodrugs | VIIV HEALTHCARE CO (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8217034-B2 | Chemical compounds | SHIONOGI & CO., LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| US-8217034-B2 | Chemical compounds | SHIONOGI & CO., LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110190236-A1 | CHEMICAL COMPOUNDS | SHIONOGI & CO., LTD. | 2011-08-04 | — | — | US | disclosed |
| US-20110190236-A1 | CHEMICAL COMPOUNDS | SHIONOGI & CO., LTD. | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011613-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | TYMP, CDK6, IMPA1 | SLC22A2 4332/4885CYP3A4 644/4885TMEM97 4179/4885 |
| US-20170368040-A1 | Processes for Preparing Dolutegravir and Cabotegravir and Analogues Thereof | SAMHD1, TYMP, DUT | SLC22A2 4748/4885CYP3A4 38/4885TMEM97 2974/4885 |
| US-20170226128-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | TYMP, CDK6, IMPA1 | SLC22A2 4332/4885CYP3A4 644/4885TMEM97 4179/4885 |
| US-20140256937-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | TYMP, CDK6, IMPA1 | SLC22A2 4332/4885CYP3A4 644/4885TMEM97 4179/4885 |
| US-20160108058-A1 | An improved process for the preparation of Dolutegravir | XDH, TBK1, POLR2H | SLC22A2 4088/4885CYP3A4 13/4885TMEM97 1184/4885 |
| US-20110190236-A1 | CHEMICAL COMPOUNDS | HPRT1, IMPDH1, IMPDH2 | SLC22A2 2056/4885CYP3A4 22/4885TMEM97 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.